Cagrilintide Demonstrates Metabolic Benefits & Reduces Alcohol Intake in the Golden Syrian Hamster, a New Preclinical Model to Evaluate Amylin-based Therapeutics

12:00 pm - Wednesday 2nd December 2026

  • Discussing the limitations of DIO mice and rats in the preclinical development of amylin-based therapeutics 
  • Introducing the golden Syrian hamster model to evaluate the effects of therapies on obesity, MASH/MetALD, and alcohol use disorders
  • Presenting the effects of the amylin analogue cagrilintide in this new hamster model

Speakers:

PhD/Director - Research & Business Development
Physiogenex